Unknown NA INTERVENTIONAL 2-arm NCT06007235

CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa (MATHBULL)

A Randomized, Double-Blind, Placebo-Controlled, Crossover, Pilot Stage Clinical Trial Evaluating CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa

Sponsor: ARANZ Medical

Conditions Epidermolysis Bullosa Dystrophica Epidermolysis Bullosa, Junctional

Interventions CACIPLIQ20 Placebo

Updated 6 times since 2023 Last updated: Feb 12, 2024 Started: Jan 29, 2024 Primary completion: Sep 30, 2024 Completion: Sep 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06007235, this NA trial focuses on Epidermolysis Bullosa Dystrophica and Epidermolysis Bullosa, Junctional and remains ongoing. Sponsored by ARANZ Medical, it has been updated 6 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Mar 2026 — Present [monthly]

Unknown NA

Status: Recruiting → Unknown
Sep 2024 — Mar 2026 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Mar 2024 — Jul 2024 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Dec 2023 — Mar 2024 [monthly]

Not Yet Recruiting NA

▶ Show 1 earlier version

Sep 2023 — Dec 2023 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ARANZ Medical
Euraxi Pharma
Organ, Tissue, Regeneration, Repair and Replacement

Data source: Organ, Tissue, Regeneration, Repair and Replacement

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France